预约演示
AbbVie ends stay with the ADAM family, dropping MacroGenics-partnered ADC in light of early data
抗体药物偶联物并购临床1期
MacroGenics has a second shot at ADAM9 in its pipeline.
MacroGenicscut short its call on ADAM9DAM family. The ADAM9-targeted antibody-drug conjugate (ADC) IMGC936 fell short of safety and efficacy expectations in solid tumors, prompting AbbVie and its equal partner MacroGenics to walk away from the candidate.
AbbVieenics worked with ImmunoGen, now part of AbbVie ADAM9-targeted0.1 billion deal, to advance thIMGC936o a phase 1 readout. ADAM9 is overexpressed in non-solid tumorsung, pancreaAbbVieastric, breast, ovarianMacroGenicsctal cancers, suggesting it could enable the safe delivery of cytotoxic payloads to tumor cells.
MacroGenicsase 1 data faImmunoGenake the case fAbbViether development of IMGC936. MacroGenics broke tADCnews after the market cADAM9 Thursday, telling investors that neither it nor AbbVie plan to advance the molecule because it “did not achieve pre-established clinical safety and efficacy benchmarks.”tumor
The statement lacks further information, but MacroGenics CEO Scott KoenigIMGC936 PMacroGenicsssed challenges facing the program on an earnings call in November, when he told investoAbbViet “identifying the appropriate dose” has always been one of the issues for IMGC936. At that time, ImmunoGen was still finishing up the lung cancer cohort, pushing back the readout from 2023 to 2024.
While the readout failed to support further dMacroGenicsof IMGC936, MacroGenics continues to believe in the potential of ADAM9. The biotech has a second shot at the target, MGC028, that uses Synaffix’s linker-payload in preclinical testing.IMGC936ImmunoGenlung cancer
MacroGenics plans to present preclinical data on MGC028 in IMGC936KoMacroGenics the presentation on an earnings call ThurADAM9 explaining that MGC028 had “specific dose-depeMGC028in vivo antiSynaffixtivity” in ADAM9-positive models, including in gastric, lung, pancreatic, colorectal, and head and neck cancers.
MacroGenics the retreat from IMGC936 eliminates aMGC028shot chance to realize additional value from the ImmunoGen takeover while leaving the coMGC028e for the deal intact. The takeover gave AbbVie control of thADAM9-positiveα-directed ADC Elahere, which could generate blockbuster sales if it moves into earlier lines of therapy, and expertise in a modality that could support the Big Pharma’s solid tumor strategy.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。